JP Morgan Chase
TBRA

JP Morgan Chase’s Tobira Therapeutics, Inc. Common Stock TBRA Stock Holding History

JP Morgan Chase’s Portfolio TBRA Stock Details TBRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-3,025
Closed -$25K – 5152
2016
Q1 		$25K Buy
+3,025
New +$22.8K ﹤0.01% 4049

Other funds holding TBRA

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

JP Morgan Chase's TBRA Position: Q2 2016 in Review

JP Morgan Chase sold out of Tobira Therapeutics, Inc. Common Stock (TBRA) in Q2 2016, closing a stake of 3,025 shares — an estimated $25K sold.

JP Morgan Chase first reported a position in TBRA in Q1 2016 and held it in 1 quarter. The position peaked at $25K in Q1 2016. 45 funds tracked by Wall St. Rank hold TBRA as of Q2 2016.

  • JP Morgan Chase reported no remaining Tobira Therapeutics, Inc. Common Stock position as of Q2 2016 after selling out during the quarter.
  • JP Morgan Chase sold 3,025 Tobira Therapeutics, Inc. Common Stock shares in Q2 2016, an estimated $25K.
  • JP Morgan Chase first reported a position in Tobira Therapeutics, Inc. Common Stock in Q1 2016 and held it in 1 quarter.
  • JP Morgan Chase's Tobira Therapeutics, Inc. Common Stock position peaked at $25K in Q1 2016.
  • 45 funds tracked by Wall St. Rank held Tobira Therapeutics, Inc. Common Stock as of Q2 2016.

Based on JP Morgan Chase's 13F filing for Q2 2016, filed 8 Aug 2016.